Objective – to determine the features of the daily profile of blood pressure (BP), blood lipid spectrum, features of left ventricular remodeling in patients with hypertension in combination with RA and to evaluate the effectiveness of using medium doses of rosuvastatin to correct dyslipidemia in this group of patients. 70 patients aged 40-65 years were examined (average – M±m – 54.88±0.96 years). Hypertensive disease in combination with rheumatoid arthritis was found in 50 patients, which made up the main group. The patients were divided into 2 subgroups: the first group included 25 patients with essential hypertension in combination with rheumatoid arthritis, who took valsartan at a dose of 80 mg at home, indapamide 1.5 mg, rosuvastatin 20 mg. The second subgroup included 25 patients who took valsartan at a dose of 80 mg / day, amlodipine at a dose of 5 mg, rosuvastatin at a dose of 20 mg. The control group (comparison) consisted of 20 patients with arterial hypertension without RA, matched by sex and age with the main groups. (3 people, 17 women, average age 55.65±1.19 years). 1. Valsartan therapy and its combination with indapamide in hypertensive patients in combination with rheumatoid arthritis led to regression of LVH in all patients, normalization of LV geometry in 33% of patients, improvement of LV diastolic function in 88.2%. 2. The addition of indapamide to therapy led to a further decrease in the average values of blood pressure at night, increased the number of patients who achieved normalization of blood pressure from 50 to 75%, while therapy with amlodipine with indapamide did not change the severity of the circadian rhythm of blood pressure and the degree of nighttime decrease in SBP and in general the group remained inadequate. 3. Changes in the diurnal blood pressure profile, found in the majority of patients with arterial hypertension in combination with rheumatoid arthritis, were characterized by increased mean daily, mean systolic blood pressure levels, increased daytime variability, and a lower degree of nocturnal decrease in comparison with patients without RA. 4. The use of 20 mg rosuvastatin as part of complex therapy in patients with hypertension in combination with RA contributed to the achievement of target levels of lipid spectrum in the blood in most patients.ent of target levels of lipid spectrum in the blood in most patients.

Author